Literature DB >> 24940101

Factors associated with breast cancer mortality after local recurrence.

R Dent1, A Valentini2, W Hanna3, E Rawlinson2, E Rakovitch4, P Sun2, S A Narod2.   

Abstract

PURPOSE: We aimed to identify risk factors for mortality after local recurrence in women treated for invasive breast cancer with breast-conserving surgery. EXPERIMENTAL
DESIGN: Our prospective cohort study included 267 women who were treated with breast-conserving surgery at Women's College Hospital from 1987 to 1997 and who later developed local recurrence. Clinical information and tumour receptor status were abstracted from medical records and pathology reports. Patients were followed from the date of local recurrence until death or last follow-up. Survival analysis used a Cox proportional hazards model.
RESULTS: Among the 267 women with a local recurrence, 97 (36.3%) died of breast cancer within 10 years (on average 2.6 years after the local recurrence). The actuarial risk of death was 46.1% at 10 years from recurrence. In a multivariable model, predictors of death included short time from diagnosis to recurrence [hazard ratio (hr) for <5 years compared with ≥10 years: 3.40; 95% confidence interval (ci): 1.04 to 11.1; p = 0.04], progesterone receptor positivity (hr: 0.35; 95% ci: 0.23 to 0.54; p < 0.001), lymph node positivity (hr: 2.1; 95% ci: 1.4 to 3.3; p = 0.001), and age at local recurrence (hr for age >45 compared with age ≤45 years: 0.61; 95% ci: 0.38 to 0.95; p = 0.03).
CONCLUSIONS: The risk of death after local recurrence varies widely. Risk factors for death after local recurrence include node positivity, progesterone receptor negativity, young age at recurrence, and short time from diagnosis to recurrence.

Entities:  

Keywords:  Breast cancer; mortality; prognostic factors; recurrence

Year:  2014        PMID: 24940101      PMCID: PMC4059805          DOI: 10.3747/co.21.1563

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  21 in total

Review 1.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.

Authors:  M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang
Journal:  Lancet       Date:  2005-12-17       Impact factor: 79.321

Review 2.  Breast cancer in young women.

Authors:  Steven A Narod
Journal:  Nat Rev Clin Oncol       Date:  2012-06-26       Impact factor: 66.675

3.  Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials.

Authors:  Irene L Wapnir; Stewart J Anderson; Eleftherios P Mamounas; Charles E Geyer; Jong-Hyeon Jeong; Elizabeth Tan-Chiu; Bernard Fisher; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

4.  Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial.

Authors:  J A van Dongen; A C Voogd; I S Fentiman; C Legrand; R J Sylvester; D Tong; E van der Schueren; P A Helle; K van Zijl; H Bartelink
Journal:  J Natl Cancer Inst       Date:  2000-07-19       Impact factor: 13.506

5.  Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy.

Authors:  Nils D Arvold; Alphonse G Taghian; Andrzej Niemierko; Rita F Abi Raad; Meera Sreedhara; Paul L Nguyen; Jennifer R Bellon; Julia S Wong; Barbara L Smith; Jay R Harris
Journal:  J Clin Oncol       Date:  2011-09-06       Impact factor: 44.544

6.  Local recurrence after breast cancer affects specific survival differently according to patient age.

Authors:  A Courdi; J Doyen; J Gal; E Chamorey
Journal:  Oncology       Date:  2011-03-23       Impact factor: 2.935

7.  Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years.

Authors:  Amye J Tevaarwerk; Robert J Gray; Bryan P Schneider; Mary Lou Smith; Lynne I Wagner; John H Fetting; Nancy Davidson; Lori J Goldstein; Kathy D Miller; Joseph A Sparano
Journal:  Cancer       Date:  2012-10-12       Impact factor: 6.860

Review 8.  Ipsilateral breast tumor recurrence: is there any evidence for benefit of further systemic therapy?

Authors:  Bhawna Sirohi; Alexandra Leary; Stephen R D Johnston
Journal:  Breast J       Date:  2009 May-Jun       Impact factor: 2.431

9.  Efficient reduction of loco-regional recurrences but no effect on mortality twenty years after postmastectomy radiation in premenopausal women with stage II breast cancer - a randomized trial from the South Sweden Breast Cancer Group.

Authors:  Fredrika Killander; Harald Anderson; Stefan Rydén; Torgil Möller; L O Hafström; Per Malmström
Journal:  Breast       Date:  2009-10-06       Impact factor: 4.380

10.  Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.

Authors:  Bernard Fisher; Stewart Anderson; John Bryant; Richard G Margolese; Melvin Deutsch; Edwin R Fisher; Jong-Hyeon Jeong; Norman Wolmark
Journal:  N Engl J Med       Date:  2002-10-17       Impact factor: 91.245

View more
  12 in total

1.  Comparison of Clinical and Pathological Differences of Breast Cancer Patients under 35 and above 55 Years of Age.

Authors:  Mustafa Emiroğlu; Cem Karaali; İsmail Sert; Semra Salimoğlu; Levent Uğurlu; Süleyman Aksoy; Cengiz Aydın
Journal:  J Breast Health       Date:  2015-07-01

2.  Semiparametric Model for Bivariate Survival Data Subject to Biased Sampling.

Authors:  Jin Piao; Jing Ning; Yu Shen
Journal:  J R Stat Soc Series B Stat Methodol       Date:  2019-01-06       Impact factor: 4.488

3.  Circulating Cell-free DNA in Serum as a Marker for the Early Detection of Tumor Recurrence in Breast Cancer Patients.

Authors:  Alakesh Bera; Eric Russ; John Karaian; Adam Landa; Surya Radhakrishnan; Madhan Subramanian; Matthew Hueman; Harvey B Pollard; Hai Hu; Craig D Shriver; Meera Srivastava
Journal:  Cancer Diagn Progn       Date:  2022-05-03

Review 4.  Late Recurrence Following Early Breast Cancer.

Authors:  Alexandra Thomas; Heather A Parsons; Karen Lisa Smith
Journal:  J Clin Oncol       Date:  2022-03-03       Impact factor: 50.717

5.  HIF-2α regulates CD44 to promote cancer stem cell activation in triple-negative breast cancer via PI3K/AKT/mTOR signaling.

Authors:  Jie Bai; Wei-Bin Chen; Xiao-Yu Zhang; Xiao-Ning Kang; Li-Jun Jin; Hui Zhang; Zun-Yi Wang
Journal:  World J Stem Cells       Date:  2020-01-26       Impact factor: 5.326

Review 6.  An Overview of PARP Inhibitors for the Treatment of Breast Cancer.

Authors:  Laura Cortesi; Hope S Rugo; Christian Jackisch
Journal:  Target Oncol       Date:  2021-03-12       Impact factor: 4.493

7.  Factors associated with the incidence of local recurrences of breast cancer in women who underwent conservative surgery.

Authors:  Juliana Rodrigues Tovar; Eliana Zandonade; Maria Helena Costa Amorim
Journal:  Int J Breast Cancer       Date:  2014-11-04

Review 8.  Is invasion a necessary step for metastases in breast cancer?

Authors:  Steven A Narod; Victoria Sopik
Journal:  Breast Cancer Res Treat       Date:  2018-01-20       Impact factor: 4.872

9.  Chest resurfacing with a reverse abdominoplasty flap for invasive breast cancer recurrence.

Authors:  Pietro G di Summa; Clara Schaffer; Sherilyn K Tay; Eva Weiler-Mithoff
Journal:  Case Reports Plast Surg Hand Surg       Date:  2019-04-23

10.  TrkA Interacts with and Phosphorylates STAT3 to Enhance Gene Transcription and Promote Breast Cancer Stem Cells in Triple-Negative and HER2-Enriched Breast Cancers.

Authors:  Angelina T Regua; Noah R Aguayo; Sara Abu Jalboush; Daniel L Doheny; Sara G Manore; Dongqin Zhu; Grace L Wong; Austin Arrigo; Calvin J Wagner; Yang Yu; Alexandra Thomas; Michael D Chan; Jimmy Ruiz; Guangxu Jin; Roy Strowd; Peiqing Sun; Jiayuh Lin; Hui-Wen Lo
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.